| Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7 P Wang, MS Nair, L Liu, S Iketani, Y Luo, Y Guo, M Wang, J Yu, B Zhang, ... Nature 593 (7857), 130-135, 2021 | 2325 | 2021 |
| Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike L Liu, P Wang, MS Nair, J Yu, M Rapp, Q Wang, Y Luo, JFW Chan, V Sahi, ... Nature 584 (7821), 450-456, 2020 | 1388 | 2020 |
| Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 L Liu, S Iketani, Y Guo, JFW Chan, M Wang, L Liu, Y Luo, H Chu, Y Huang, ... Nature 602 (7898), 676-681, 2022 | 1149 | 2022 |
| Increased resistance of SARS-CoV-2 variant P. 1 to antibody neutralization P Wang, RG Casner, MS Nair, M Wang, J Yu, G Cerutti, L Liu, PD Kwong, ... Cell host & microbe 29 (5), 747-751. e4, 2021 | 937 | 2021 |
| Antibody evasion properties of SARS-CoV-2 Omicron sublineages S Iketani, L Liu, Y Guo, L Liu, JFW Chan, Y Huang, M Wang, Y Luo, J Yu, ... Nature 604 (7906), 553-556, 2022 | 750 | 2022 |
| Antibody evasion by SARS-CoV-2 Omicron subvariants BA. 2.12. 1, BA. 4 and BA. 5 Q Wang, Y Guo, S Iketani, MS Nair, Z Li, H Mohri, M Wang, J Yu, ... Nature 608 (7923), 603-608, 2022 | 657 | 2022 |
| Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants Q Wang, S Iketani, Z Li, L Liu, Y Guo, Y Huang, AD Bowen, M Liu, ... Cell 186 (2), 279-286. e8, 2023 | 534 | 2023 |
| Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite G Cerutti, Y Guo, T Zhou, J Gorman, M Lee, M Rapp, ER Reddem, J Yu, ... Cell host & microbe 29 (5), 819-833. e7, 2021 | 455 | 2021 |
| Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo … S Yang, Y Li, L Dai, J Wang, P He, C Li, X Fang, C Wang, X Zhao, ... The Lancet Infectious Diseases 21 (8), 1107-1119, 2021 | 409 | 2021 |
| Antibody response to omicron BA. 4–BA. 5 bivalent booster Q Wang, A Bowen, R Valdez, C Gherasim, A Gordon, L Liu, DD Ho New England Journal of Medicine 388 (6), 567-569, 2023 | 168* | 2023 |
| Real-time conformational dynamics of SARS-CoV-2 spikes on virus particles M Lu, PD Uchil, W Li, D Zheng, DS Terry, J Gorman, W Shi, B Zhang, ... Cell host & microbe 28 (6), 880-891. e8, 2020 | 159 | 2020 |
| SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease P Wang, L Liu, MS Nair, MT Yin, Y Luo, Q Wang, T Yuan, K Mori, AG Solis, ... Emerging microbes & infections 9 (1), 2091-2093, 2020 | 133 | 2020 |
| Cryo-EM structure of the SARS-CoV-2 Omicron spike G Cerutti, Y Guo, L Liu, L Liu, Z Zhang, Y Luo, Y Huang, HH Wang, DD Ho, ... Cell reports 38 (9), 2022 | 85 | 2022 |
| Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA. 2.75 Q Wang, S Iketani, Z Li, Y Guo, AY Yeh, M Liu, J Yu, Z Sheng, Y Huang, ... Cell host & microbe 30 (11), 1512-1517. e4, 2022 | 75 | 2022 |
| A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike B Dadonaite, KHD Crawford, CE Radford, AG Farrell, CY Timothy, ... Cell 186 (6), 1263-1278. e20, 2023 | 65 | 2023 |
| Resistance of SARS-CoV-2 omicron subvariant BA. 4.6 to antibody neutralisation Q Wang, Z Li, J Ho, Y Guo, AY Yeh, H Mohri, M Liu, M Wang, J Yu, ... The Lancet Infectious Diseases 22 (12), 1666-1668, 2022 | 60 | 2022 |
| Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class M Rapp, Y Guo, ER Reddem, J Yu, L Liu, P Wang, G Cerutti, P Katsamba, ... Cell Reports 35 (1), 2021 | 59 | 2021 |
| Structure-based design with tag-based purification and in-process biotinylation enable streamlined development of SARS-CoV-2 spike molecular probes T Zhou, IT Teng, AS Olia, G Cerutti, J Gorman, A Nazzari, W Shi, ... Cell Reports 33 (4), 2020 | 59 | 2020 |
| Antigenicity and receptor affinity of SARS-CoV-2 BA. 2.86 spike Q Wang, Y Guo, L Liu, LT Schwanz, Z Li, MS Nair, J Ho, RM Zhang, ... Nature 624 (7992), 639-644, 2023 | 58 | 2023 |
| Structural basis for accommodation of emerging B. 1.351 and B. 1.1. 7 variants by two potent SARS-CoV-2 neutralizing antibodies G Cerutti, M Rapp, Y Guo, F Bahna, J Bimela, ER Reddem, J Yu, P Wang, ... Structure 29 (7), 655-663. e4, 2021 | 58 | 2021 |
Yicheng GuoColumbia UniversityПотвърден имейл адрес: cumc.columbia.edu
